Reach Us +44-1202-068036
Involvement Of Genetics In Poor Outcomes In Anticoagulation Therapy | 32926
ISSN: 2157-7609

Journal of Drug Metabolism & Toxicology
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Involvement of genetics in poor outcomes in anticoagulation therapy

International Conference on Toxicogenomics and Drug Monitoring

Farhad Kamali

Newcastle University, UK

ScientificTracks Abstracts: J Drug Metab Toxicol

DOI: 10.4172/2157-7609.S1.001

Warfarin is commonly prescribed for the treatment and prevention of thromboembolic disorders. Anticoagulation response to warfarin during the initiation of therapy is variable. This is mainly due to the drug’s narrow therapeutic window and the wide inter-individual variability in warfarin dose requirement which makes the prediction of an accurate dose for individual patients difficult despite the use of standard induction regimens and frequent INR monitoring. As a result, some patients who are sensitive to warfarin are at increased risk of bleeding due to over-dosing whereas some are at increased risk of thrombosis due to underdosing. Approximately half of the variability in warfarin dose requirement is explained by patient age, body size and CYP2C9 and VKORC1 genes. A personalized approach to warfarin dosing using genetic information has the potential to improve the safety and efficacy of anticoagulation therapy. The author will be presenting the results of prospective trials exploring the potential benefits of pharmacogenetics-based therapy and the potential for future implementation of pharmacogenetics-guided therapy in the clinic setting.

Farhad Kamali is Professor of Human & Experimental Pharmacology at the Institute of Cellular Medicine, Newcastle University, United Kingdom. He has published well over one hundred articles in peer reviewed journals as well as book chapters. He serves on the editorial board of a number of journals in the areas of clinical pharmacology, pharmacogenetics and haematology. His research focuses on the elucidation of the mechanisms of drug-induced toxicity and in particular identifying the risk factors associated with poor outcomes in anticoagulation treatment of thromboembolic disease.

Email: [email protected]

Relevant Topics
Leave Your Message 24x7